| Assessment Status | Rapid Review Complete |
| HTA ID | 22038 |
| Drug | Risankizumab |
| Brand | Skyrizi® |
| Indication | Alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). |
| Assessment Process | |
| Rapid review commissioned | 30/05/2022 |
| Rapid review completed | 30/06/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that risankizumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having so having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations October 2022.
